Metastatic liposarcoma is a rare and serious condition where cancer that started in fat cells has spread to other parts of the body. Understanding the diagnostic process is essential for patients and their families, as it helps determine the best approach to care and provides important information about the disease’s extent and characteristics.
Introduction: Who Should Undergo Diagnostics
If you have been diagnosed with liposarcoma or have completed treatment for this cancer, regular diagnostic testing becomes an important part of your healthcare routine. People who should seek diagnostic evaluations include those who notice unusual lumps or masses that don’t go away, especially if these growths increase in size over time. Since liposarcoma typically affects individuals between ages 50 and 65, people in this age group should be particularly attentive to any persistent changes in their body.[2]
You should consider diagnostic testing if you experience symptoms such as a growing lump under your skin, particularly in your arms, legs, or abdomen. Pain in the affected region, swelling, or weakness of a limb can also signal the need for medical evaluation. When liposarcoma occurs in the abdomen, symptoms might include abdominal pain, swelling, feeling full sooner when eating, constipation, or blood in stool.[3] These signs warrant prompt medical attention because early detection of cancer spread can influence treatment decisions.
For patients already diagnosed with liposarcoma, regular follow-up diagnostic testing is crucial. Some types of liposarcoma, particularly dedifferentiated liposarcoma (a more aggressive form that develops from well-differentiated tumors) and myxoid liposarcoma, have the potential to spread to distant parts of the body. Dedifferentiated liposarcoma primarily spreads to the lungs, while myxoid liposarcoma can metastasize to unusual locations including the spine, soft tissues in other parts of the body, and fat deposits in various areas.[5]
Patients who have completed treatment should maintain regular surveillance even years after their initial diagnosis. Some liposarcomas have a high local recurrence rate, meaning the cancer can come back in the same area where it started, even up to 25 years after the original tumor was removed.[2] This long timeframe emphasizes why consistent follow-up care and diagnostic monitoring are essential components of survivorship.
Diagnostic Methods
The diagnostic journey for metastatic liposarcoma typically begins when either a patient notices new symptoms or when routine surveillance imaging detects concerning changes. Your healthcare provider will start with a thorough physical examination, looking at and feeling any lumps or areas of concern. This initial assessment helps determine which additional tests might be needed.[8]
Imaging Studies
Imaging tests play a central role in diagnosing metastatic liposarcoma and determining how far the cancer has spread. These tests create detailed pictures of the inside of your body without requiring surgery. A computed tomography (CT) scan uses X-rays and computer technology to produce cross-sectional images of your body. This test is particularly useful for detecting lung metastases, which are the most common sites where liposarcoma spreads.[5]
Magnetic resonance imaging (MRI) uses powerful magnets and radio waves instead of X-rays to create detailed images of soft tissues. MRI is especially valuable for examining liposarcoma because these tumors arise from fat cells, and MRI can clearly distinguish different types of soft tissue. This imaging method helps doctors assess the size and location of tumors and can reveal characteristics that suggest whether a tumor is likely to be cancerous.[4]
For myxoid liposarcoma specifically, imaging studies are particularly important because this subtype can spread to unusual locations. Unlike other sarcomas that typically spread only to the lungs, myxoid liposarcoma can metastasize to the spine, fatty tissue deposits in the armpits, and the retroperitoneal fat (the area at the back of the abdomen). Therefore, comprehensive imaging of multiple body regions may be necessary.[5][6]
Ultrasound examinations use sound waves to create images and can be helpful in examining certain areas of the body. A pelvic ultrasound might be used if there is concern about cancer spread to that region.[4] Chest X-rays can provide a quick initial look at the lungs, though CT scans offer more detailed information when metastases are suspected.
Tissue Sampling and Biopsy
While imaging tests can strongly suggest that cancer has spread, a biopsy (the removal and examination of a small tissue sample) provides definitive confirmation. During a biopsy procedure, a doctor removes a piece of suspicious tissue so it can be examined under a microscope by a pathologist, a physician who specializes in diagnosing diseases by studying cells and tissues.[8]
The type of biopsy performed depends on where the suspected metastasis is located. For lung nodules, various techniques might be used depending on the size and location of the abnormality. For accessible lumps or masses, a needle biopsy might be sufficient. In other cases, a surgical biopsy may be necessary to obtain enough tissue for accurate diagnosis.
The pathologist examines the biopsy tissue to confirm whether cancer cells are present and to identify their characteristics. Different subtypes of liposarcoma have distinct appearances under the microscope. Well-differentiated liposarcoma cells look relatively similar to normal fat cells, while dedifferentiated liposarcoma shows more abnormal cell features. The term “round cell” in round cell liposarcoma refers to how the tumor cells appear when viewed microscopically—they have a rounded shape rather than the elongated appearance of normal fat cells.[4]
Blood Tests and Laboratory Evaluation
Although no specific blood test can diagnose liposarcoma or detect its spread, laboratory tests remain an important part of the overall diagnostic evaluation. Blood work helps assess your general health status, organ function, and readiness for potential treatments. These tests might include complete blood counts, liver function tests, kidney function tests, and other assessments that provide information about how your body is functioning.
Research is ongoing to identify biological markers in the blood that might help detect liposarcoma spread earlier or monitor response to treatment, but these are not yet part of standard clinical practice for most patients.
Distinguishing Metastatic Liposarcoma from Other Conditions
One of the challenges in diagnosing metastatic liposarcoma is distinguishing it from other conditions. Not every lump is cancerous, and it’s important to differentiate liposarcoma from a lipoma, which is a benign (noncancerous) fatty tumor. Lipomas are much more common than liposarcomas—on average, two out of every 1,000 people develop a lipoma.[7]
Your doctor evaluates several characteristics to distinguish between these conditions. Lipomas typically feel soft and rubbery, while liposarcomas are usually firmer to the touch. Location matters as well: lipomas often form just below the skin, whereas liposarcomas typically grow deeper in the tissues. Size provides another clue—lipomas are generally no larger than 2 inches across, while liposarcomas can grow much larger, especially in areas like the retroperitoneum. Neither condition typically causes pain initially, though liposarcomas may cause discomfort as they grow and press on nerves or organs.[7]
When metastatic disease is suspected, doctors must also consider other types of cancer that commonly spread to the lungs or other organs. The biopsy and microscopic examination help confirm that the spreading cancer is indeed liposarcoma rather than another type of tumor.
Diagnostics for Clinical Trial Qualification
Clinical trials are research studies that test new treatments or approaches to care. For patients with metastatic liposarcoma, clinical trials may offer access to promising new therapies that are not yet widely available. However, entering a clinical trial requires meeting specific diagnostic criteria to ensure the study results will be meaningful and that participants receive appropriate care.
Tissue Confirmation Requirements
Most clinical trials for metastatic liposarcoma require confirmation that you have a specific subtype of the disease. This means you must have had a biopsy, and a pathologist must have examined the tissue to determine exactly what type of liposarcoma you have. Some studies may require fresh biopsy tissue, while others accept archived tissue from previous biopsies or surgeries. The reason for this requirement is that different subtypes of liposarcoma respond differently to treatments—for instance, myxoid liposarcoma is considered relatively chemosensitive compared to well-differentiated and dedifferentiated tumors.[11]
Research has shown that the response rates to chemotherapy vary considerably among different histological subtypes of liposarcoma. In retrospective analyses, myxoid liposarcoma demonstrated better response to chemotherapy compared to other liposarcoma types, particularly dedifferentiated and well-differentiated tumors. This finding has important implications for clinical trial design and patient selection.[11]
Staging and Disease Extent Documentation
Clinical trials typically require detailed documentation of where the cancer has spread and how much disease is present. This process, called staging, involves comprehensive imaging studies to map all areas affected by cancer. For liposarcoma trials, this usually includes CT scans of the chest to check for lung metastases, and may include imaging of the abdomen, pelvis, and other regions depending on the specific subtype and pattern of spread.
The extent of disease documentation helps researchers ensure that trial participants have similar disease burdens, which makes it easier to determine whether a new treatment is effective. It also helps ensure patient safety by identifying individuals for whom an experimental treatment might pose too great a risk.
Prior Treatment History
Many clinical trials for metastatic disease specify whether patients must have received previous treatment or whether they should be treatment-naive (never treated before). Some studies specifically enroll patients whose cancer has continued growing despite standard chemotherapy. For example, trials that led to the approval of trabectedin and eribulin for liposarcoma specifically enrolled patients who had received prior treatment with anthracycline-containing chemotherapy regimens.[11]
Your medical team will need to document what treatments you have received, how your cancer responded, and any side effects you experienced. This information helps determine whether you meet the eligibility criteria for specific trials and helps researchers understand how the experimental treatment performs in patients with different treatment histories.
Functional Status Assessment
Clinical trials assess your overall health and ability to carry out daily activities, often using standardized scales. These assessments help determine whether you are healthy enough to tolerate an experimental treatment and whether you can safely participate in the study requirements, which might include frequent clinic visits and additional testing.
Molecular and Genetic Testing
Advances in understanding the molecular characteristics of liposarcoma have led to the development of new targeted therapies. Well-differentiated and dedifferentiated liposarcomas are particularly associated with specific genetic changes in chromosome 12, involving oncogenes including CDK4 and MDM2. These genetic aberrations represent potential targets for new treatments.[9]
Some clinical trials may require molecular testing of your tumor tissue to identify specific genetic changes. Comprehensive genomic profiling, which examines many genes at once, may facilitate targeted therapy for individual liposarcomas in the future.[11] While these molecular tests are not yet standard for all patients, they are becoming increasingly important in research settings and may help match patients with the most appropriate experimental treatments.
Baseline Laboratory Values
Before enrolling in a clinical trial, you will undergo comprehensive blood testing to establish baseline values for various measurements. These tests assess organ function, particularly of the liver, kidneys, heart, and bone marrow. The results help determine whether you can safely receive the experimental treatment and provide a baseline against which future tests can be compared to monitor for side effects.
Trial protocols specify acceptable ranges for laboratory values. For example, liver function tests must typically fall within certain limits because many cancer drugs are processed by the liver. Similarly, blood cell counts must be adequate to ensure your body can tolerate chemotherapy if that is part of the experimental treatment.
